Treatment of advanced-stage Hodgkin lymphoma

Seminars in Hematology

Volumn 53, Issue 3, 2016, Pages 171-179

  Vassilakopoulos, Theodoros P ^a   Johnson, Peter W M ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

ABVD; Advanced stages; BEACOPP; Interim PET; Positron emission tomography (PET)

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; DRUG EFFICACY; HODGKIN DISEASE; HUMAN; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SALVAGE THERAPY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84991222534     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2016.05.006     Document Type: Review

References (66)

1. [1] De Vita, V.T., Serpick, A.A., Carbone, P.P., Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73 (1970), 891–895.
2. [2] Bonadonna, G., Historical review of Hodgkin's disease. Br J Haematol 110 (2000), 504–511.
3. [3] Canellos, G.P., Rosenberg, S.A., Friedberg, J.W., Lister, T.A., Devita, V.T., Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol 32 (2014), 163–168.
4. [4] Vassilakopoulos, T.P., Angelopoulou, M.K., Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years. Semin Hematol 50 (2013), 4–14.
5. [5] Johnson, P., McKenzie, H., How I treat advanced classical Hodgkin lymphoma. Blood 125 (2015), 1717–1723.
6. [6] Bonadonna, G., Zucali, R., Monfardini, S., De Lena, M., Uslenghi, C., Combination chemotherapy of Hodgkin׳s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36 (1975), 252–259.
7. [7] Bonadonna, G., Chemotherapy strategies to improve the control of Hodgkin׳s disease. The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 42 (1982), 4309–4320.
8. [8] Canellos, G.P., Anderson, J.R., Propert, K.J., et al. Chemotherapy of advanced Hodgkin׳s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 (1992), 1478–1484.
9. [9] Duggan, D.B., Petroni, G.R., Johnson, J.L., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an Intergroup trial. J Clin Oncol 21 (2003), 607–614.
10. [10] Johnson, P.W.M., Radford, J.A., Cullen, M.H., et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 trial (ISRCTN97144519). J Clin Oncol 23 (2005), 9208–9218.
11. [11] Gobbi, P.G., Levis, A., Chisesi, T., et al. ABVD vs. modified Stanford V vs. MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma. Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23 (2005), 9198–9207.
12. [12] Federico, M., Luminari, S., Ianitto, E., et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi trial. J Clin Oncol 27 (2009), 805–811.
13. [13] Loeffler, M., Hasenclever, D., Diehl, V., Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. Ann Oncol 9:suppl 5 (1998), S73–S78.
14. [14] Tesch, H., Diehl, V., Lathan, B., et al. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Blood 92 (1998), 4560–4567.
15. [15] Diehl, V., Franklin, J., Pfreundschuh, M., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348 (2003), 2386–2395.
16. [16] Engert, A., Diehl, V., Franklin, J., et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 20 (2009), 4548–4554.
17. [17] Engert, A., Haverkamp, H., Kobe, C., et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379 (2012), 1791–1799.
18. [18] Merli, F., Luminari, S., Gobbi, P.G., et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol 34 (2016), 1175–1181.
19. [19] Viviani, S., Zinzani, P.L., Rambaldi, A., et al. ABVD versus BEACOPP for Hodgkin׳s lymphoma when high-dose salvage is planned. N Engl J Med 365 (2011), 203–212.
20. baseline in stage III to IV, international prognostic score ≥ 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup trial. J Clin Oncol 34 (2016), 2028–2036.
21. [21] Mounier, N., Brice, P., Bologna, S., et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 25 (2014), 1622–1628.
22. [22] Borchmann, P., Haverkamp, H., Diehl, V., et al. Eight cycles of escalated dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 29 (2011), 4234–4242.
23. [23] Skoetz, N., Trelle, S., Rancea, M., et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. Lancet Oncol 14 (2013), 943–952.
24. [24] Federico, M., Bellei, M., Cheson, B.D., BEACOPP or no BEACOPP?. Lancet Oncol 14 (2013), e487–e488.
25. [25] Hasenclever, D., Diehl, V., for the International Prognostic Factors Project on Advanced Hodgkin's Disease. A prognostic score for advanced Hodgkin's disease. N Engl J Med 339 (1998), 1506–1514.
26. [26] Moccia, A.A., Donaldson, J., Chhanabhai, M., et al. International prognostic score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. J Clin Oncol 30 (2012), 3383–3388.
27. [27] Vassilakopoulos, T., Kanellopoulos, A., Pangalis, G., et al. Validation of the International Prognostic Score in patients with advanced Hodgkin lymphoma treated with anthracycline-based chemotherapy. Haematol Hematol J, 97(Suppl 1), 2012, 216.
28. [28] Diefenbach, C.S., Li, H., Hong, F., et al. Evaluation of the international prognostic score (IPS-7) and a simpler prognostic score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol 171 (2015), 530–538.
29. [29] Hoskin, P.J., Lowry, L., Horwich, A., et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 27 (2009), 5390–5396.
30. [30] Guisado-Vasco, P., Arranz, R., Canales, M., et al. Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. Leuk Lymphoma 53 (2012), 812–819.
31. [31] Gordon, L.I., Hong, F., Fisher, R.I., et al. Randomized phase III trial of ABVD versus. Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An Intergroup Study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 31 (2013), 684–691.
32. [32] Broeckelman, P., Angelopoulou, M.K., Vassilakopoulos, T.P., Prognostic factors in Hodgkin lymphoma. Semin Hematol., 2016 http://dx.doi.org/10.1053/j.seminhematol.2016.05.003.
33. [33] Hutchings, M., Loft, A., Hansen, M., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 (2006), 52–59.
34. [34] Gallamini, A., Hutchings, M., Rigacci, L., et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin׳s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25 (2007), 3746–3752.
35. [35] Meignan, M., Gallamini, A., Haioun, C., Polliack, A., Report on the second international workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 51 (2010), 2171–2180.
36. [36] Cheson, B.D., Fisher, R.I., Barrington, S.F., et al. Recommendations for the initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32 (2014), 3059–3067.
37. [37] Barrington, S.F., Mikhaeel, G.N., Kostakoglu, L., et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32 (2014), 3048–3058.
38. [38] Gallamini, A., Barrington, S.F., Biggi, A., et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 99 (2014), 1107–1113.
39. [39] Biggi, A., Gallamini, A., Chauvie, S., et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med 54 (2013), 683–690.
40. [40] Gallamini, A., Kostakoglou, L., Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?. Blood 120 (2012), 4913–4920.
41. [41] Vassilakopoulos, T.P., Prassopoulos, V., Rondogianni, P., et al. Role of FDG-PET/CT in staging and first-line treatment of Hodgkin and aggressive B-cell lymphomas. Memo 8 (2015), 105–114.
42. [42] Gallamini, A., Patti, C., Viviani, S., et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 152 (2011), 551–560.
43. [43] Johnson, P., Federico, M., Kirkwood, A., et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin`s lymphoma. N Engl J Med 374 (2016), 2419–2429.
44. [44] Gallamini, A., Rossi, A., Patti, C., et al. Interim PET-adapted chemotherapy in advanced Hodgkin lymphoma (HL). Results of the second interim analysis of the Italian GITIL/FIL DH0607 trial. Hematol Oncol, 33(S1), 2015, 163 (abstr 118).
45. [45] Press, O., Li, H., Schoder, H., et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol 34 (2016), 2020–2027.
46. [46] Ganesan, P., Rajendranath, R., Kannan, K., et al. Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma. Ann Oncol 26 (2015), 1170–1174.
47. [47] Vassilakopoulos, T., Rondogianni, F., Boutsikas, G., et al. PET/CT for the early interim evaluation of response in advanced Hodgkin lymphoma after ABVDx2: effective salvage with BEACOPP but low negative predictive value for stage IV. Hematol Oncol, 33(S1), 2015, 313 (abstr 463).
48. [48] Zinzani, P.L., Broccoli, A., Gioia, D., et al. Interim PET response-adapted therapy in advanced stage Hodgkin's lymphoma: final results of the phase II part of the Fondazione Italiana Linfomi (FIL) HD0801 study. Hematol Oncol, 33(S1), 2015, 164 (abstr 119).
49. [49] Cimino G, Zaucha JM, Cirillo S, et al. The complementary prognostic role of baseline and interim PET in predicting treatment outcome in advanced-stage Hodgkin lymphoma Blood (ASH Annual Meeting Abstracts). 2014;124:abstr 4405.
50. [50] Oki, Y., Chuang, H., Chasen, B., et al. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165 (2014), 112–116.
51. [51] Vassilakopoulos, T.P., Angelopoulou, M.K., Siakantaris, M.P., et al. Very late relapses in patients with Hodgkin׳s lymphoma. Haematol Hematol J, 90(Suppl 2), 2005, 72.
52. [52] Viviani, S., Mussetti, A., Di Bartolo, O., et al. Late relapse in Hodgkin lymphoma (HL): a retrospective analysis of patients enrolled on clinical trials at the Istituto Nazionale Tumori of Milan (INT-MI). Blood, 126(23), 2015, 2697 (abstr).
53. [53] Johnson, P.W., Federico, M., Fossa, A., et al. Response-adapted therapy based on interim FDG-PET scans in advanced Hodgkin lymphoma: first analysis of the safety of de-escalation and efficacy of escalation in the international RATHL study. Hematol Oncol, 33(S1), 2015, 102 (abstr 008).
54. [54] Agostinelli, C., A clinical-pathological algorithm based on the combination of interim PET with biological markers in classical Hodgkin lymphoma. Presented at the Fifth International Workshop on PET in Lymphoma, Menton, 19–20 September 2014 http://eitti.free.fr.
55. escalated to improve the outcome of early interim PET positive advanced stage Hodgkin lymphoma patients: second planned interim analysis of the HD18 study. Blood (ASH Annual Meeting Abstracts) 2014;124:abstr 500.
56. [56] Casasnovas, O., Brice, P., Bouabdallah, R., et al. Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Interim analysis of the AHL2011 Lysa study. Blood, 126, 2015, 577 (abstr).
57. [57] von Tresckow, B., Plutschow, A., Fuchs, M., et al. Dose-Intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30 (2012), 907–913.
58. [58] Hutchings, M., Kostakoglu, L., Zaucha, J.M., et al. In vivo treatment sensitivity with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. J Clin Oncol 32 (2014), 2705–2711.
59. [59] Rossi, C., Kanoun, S., Berriolo-Riedinger, A., et al. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J Nucl Med 55 (2014), 569–573.
60. [60] Gibb, A., Greystoke, A., Ranson, M., et al. A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. Br J Cancer 109 (2013), 2560–2565.
61. DD-DI) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma. Br J Haematol 166 (2014), 118–129.
62. [62] Younes, A., Gopal, A.K., Smith, S.C., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30 (2012), 2183–2189.
63. [63] Younes, A., Connors, J.M., Park, S.I., et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-esclation study. Lancet Oncol 14 (2013), 1348–1356.
64. [64] Connors, J.M., Ansell, S., Park, S.I., et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed advanced stage Hodgkin lymphoma: Long term outcomes. Blood, 126, 2015, 292 (abstr).
65. [65] ECHELON 1: https://clinicaltrials.gov/ct2/show/NCT01712490.
66. [66] Borchmann, P., Eichenauer, D.A., Pluetschow, A., et al. Targeted BEACOPP variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: final analysis of a randomized phase II study. Blood, 126, 2015, 580 (abstr).